Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression-free survival.
from Top Health News – ScienceDaily http://bit.ly/2oY2xLq
from Tumblr http://bit.ly/2pnzx3l
No comments:
Post a Comment